Movement Alert｜Novo Nordisk Rises 3.15% Overnight, CEO Announces Oral Wegovy Filing in China and Additional Investment During First Visit

Market Focus06-22

On June 22, Novo Nordisk rose 3.15% overnight, trading at $44.56/share, with turnover of $1.6492 million.

On the news front, Novo Nordisk CEO Maziar Mike Doustdar made his first visit to China since assuming office, releasing multiple positive signals. The company announced plans to submit an oral version of Wegovy for regulatory approval in China within the coming months, while also revealing intentions to increase business development transactions with Chinese companies. Doustdar stated the company is in active dialogue with multiple Chinese firms and will not hesitate to make offers when suitable molecules or companies are identified.

Additionally, Novo Nordisk announced an additional RMB 200 million investment in its Tianjin strategic production base to boost assembly capacity for 1.5mL FlexTouch injection pens. On the international front, oral Wegovy recently received approval from UK regulators, becoming the first European market to approve the drug, with clinical data showing an average weight loss of 13.6% over 64 weeks. The China submission combined with ongoing overseas expansion reinforces Novo Nordisk's global commercialization outlook in the GLP-1 space, as the company races to catch up with Eli Lilly, which submitted its oral obesity drug application in China late last year.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment